Éric Gervais, Executive Vice-President of Medunik Canada, is proud to announce the Management Team of this recently created company. Medunik Canada is a Quebec pharmaceutical company with 60 employees and one unique mission – bring novel orphan drugs to Canadians with rare diseases. To this end, the Company is actively working at offering strategic partnerships to international orphan drug companies that contemplate to introduce their orphan drugs on the Canadian market.
Medunik Canada’s Executive Vice-President said: “We are proud to have a team whose commitment and excellence have allowed to build on our success. Moreover, the Medunik Canada team has a proven record of commercializing specialized small-market size products for underserved populations with specific medical needs. Medunik Canada’s team members are individually and collectively committed to dedicate their experience and expertise to bringing currently unavailable orphan drugs to Canadian with rare diseases.”
Medunik Canada’s Executive Vice-President, explained the company’s business approach: “Through in-licensing partnership, Medunik Canada is bridging the gap by providing turn-key operations – ranging from regulatory approval strategy to post-approval activities – to assure the commercial success of the partners’ novel orphan treatments. Our long-standing success in specialty markets, coupled with our solid and independent financial backing, our infrastructure and our team’s dedication to medically unique populations makes Medunik Canada a strategic fit for our partners with a global orphan drug strategy.”
Source : Médunik Canada